Brief: Belite Bio Presents Results from a 24-month, Phase 2 Study of Tinlarebant in Childhood-onset Stargardt Disease
06/11/2023 14:16
Nov 6 (Reuters) - Belite Bio Inc BLTE.O :
* BELITE BIO PRESENTS RESULTS FROM A 24-MONTH, PHASE 2 STUDY
OF
TINLAREBANT IN CHILDHOOD-ONSET STARGARDT DISEASE AT THE AAO
ANNUAL MEETING
* BELITE BIO INC - TINLAREBANT WAS SAFE AND WELL-TOLERATED
IN ALL
SUBJECTS THROUGHOUT 24-MONTH TREATMENT PERIOD
* BELITE BIO INC - FULL ENROLLMENT OF A TWO-YEAR GLOBAL
PHASE 3
STUDY OF TINLAREBANT IN CHILDHOOD-ONSET STGD1 ( "DRAGON" STUDY)
IS COMPLETE
Source text for Eikon: ID:nGNX1WYnhY
Further company coverage: BLTE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Belite Bio
See all newsBrief: Belite Bio Announces Uplisting To The Nasdaq Global Select Market
Brief: Belite Bio Announces Multi-Market Submission Of Marketing Authorization Applications Via The Access Consortium Pathway For Tinlarebant For The Treatment Of Stargardt Disease Type 1
Brief: Belite Bio Announces Submission Of New Drug Application To The Ministry Of Health, Labour, And Welfare In Japan Under The Sakigake Designation System For Tinlarebant For The Treatment Of Stargardt Disease Type 1
Belite Bio, Inc reports results for the quarter ended June 30 - Earnings Summary
Belite Bio Q2 net loss widens on higher expenses